Inxmed (Nanjing) Co. Ltd. has divulged antibody-drug conjugates comprising an antibody targeting integrin α-2 β1 (ITGA2; CD49b; VLA-2) covalently linked to a cytotoxic drug reported to be useful for the treatment of cancer.

Adlai Nortye Ltd. has submitted a clinical trial notification (CTN) to Australia’s Therapeutic Goods Administration (TGA) and received approval from the Human Research Ethics Committee (HREC) to initiate a phase I trial of AN-4035 in patients with CEACAM5-enriched RAS-addicted solid tumors.

Sunrock Biopharma SL has disclosed antibody-drug conjugates (ADCs) comprising an antibody targeting C-C chemokine receptor type 9 (CCR9) linked to camptothecin derivatives through a linker found to be potentially useful for the treatment of cancer.